Want to see LFVN full AI Analyst Report?
LifeVantage (LFVN) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 27, 2026
Risk Change Over Time
- Technology - Risk 1Our adoption, deployment, use or integration of artificial intelligence technologies may present operational, competitive, legal, regulatory, cybersecurity, privacy, reputational and other risks, and may not achieve the benefits we expect.
We have used, and may increasingly use, artificial intelligence, machine learning, generative artificial intelligence and other automated technologies, tools and systems, which we refer to collectively as AI technologies, in connection with our business, including to support internal operations, data analysis, customer and independent consultant engagement, sales and marketing activities, technology-enabled consultant tools and resources, product development, forecasting, compliance monitoring, and other business functions. We may also rely on third-party vendors, service providers or platforms that incorporate AI into the products or services they provide to us. The adoption, deployment and use of AI technologies are rapidly evolving and involve significant risks and uncertainties, and there can be no assurance that our use of AI technologies will improve our business prospects, results of operations, and financial condition. AI technologies may produce inaccurate, incomplete, misleading, biased, discriminatory, offensive or otherwise flawed outputs, content, recommendations, or analyses. If we, our employees, independent consultants, customers, vendors or other third parties rely on such outputs, content, recommendations, or analyses without appropriate human oversight, controls, testing or governance, our business prospects, results of operations, and financial condition may be adversely affected. In particular, reliance on AI-generated outputs in areas subject to existing regulatory orders or compliance commitments applicable to our business could heighten our exposure to enforcement actions or other adverse consequences. Our independent consultants may use AI technologies to create or distribute marketing content, product claims, testimonials, income or lifestyle representations, or other communications relating to our products or business opportunity. We have limited visibility into, or control over, how consultants use AI technologies, and AI-generated content could include inaccurate, unsubstantiated, or non-compliant health claims, efficacy claims, income claims, or other statements that may violate applicable laws and regulations, including the Federal Food, Drug, and Cosmetic Act, the FTC Act, or the terms of any regulatory orders or agreements applicable to our business. The FTC and other regulators have signaled increased focus on AI-generated testimonials, endorsements, and health-related claims in the direct selling and health and wellness sectors, which heightens the regulatory risk associated with consultant use of AI technologies. Any such violations could result in regulatory investigations, enforcement actions, fines, penalties, injunctive relief, litigation, reputational harm, or disruption to our business. If we are unable to adopt, integrate, govern and scale AI technologies effectively, or if competitors adopt AI technologies more rapidly or cost-efficiently than we do, our competition position, business prospects, results of operations, and financial condition may be adversely affected. Separately, if we implement AI technologies without sufficient controls, such as monitoring, training, data quality, human review or cybersecurity safeguards, we could incur additional costs, operational disruption, reputational harm or legal liability that may adversely affect our business prospects, results of operations, and financial condition. The legal and regulatory landscape applicable to AI technologies is developing rapidly and remains uncertain. Existing laws and regulations, including those relating to privacy, data protection, consumer protection, advertising, employment, intellectual property, cybersecurity, unfair or deceptive acts or practices, automated decision-making and discrimination, may be interpreted or applied to AI technologies in new or changing ways. New AI-specific laws, regulations, standards and guidance are being considered or adopted in the United States and in foreign jurisdictions in which we operate or may operate. Compliance with these requirements may increase our costs, require changes to our business practices, restrict our ability to use certain AI technologies, require enhanced transparency, testing, documentation, governance, training or monitoring, or expose us to regulatory investigations, fines, penalties, litigation or other proceedings. In addition, intellectual property ownership and license rights relating to AI systems, training data, inputs and outputs remain uncertain and continue to be the subject of litigation and regulatory attention. Our use of AI technologies could result in claims that we have infringed, misappropriated or otherwise violated third-party intellectual property rights, contractual terms, website terms of service, privacy rights or other rights, or could limit our ability to protect our own proprietary information and intellectual property. AI may also increase cybersecurity, privacy and data governance risks. AI technologies may process, store or generate personal, confidential, proprietary or sensitive information, including information relating to customers, independent consultants, employees, vendors or our business. Any improper disclosure, misuse, unauthorized access, retention or transmission of such information through AI technologies, including through third-party AI platforms, could result in data loss, security incidents, violations of privacy or data protection laws, contractual breaches, litigation, regulatory enforcement, reputational harm or other adverse consequences. In addition, malicious actors may use AI technologies to conduct more sophisticated phishing, fraud, social engineering, impersonation, misinformation, cyberattacks or other activities targeting us, our employees, our independent consultants, our customers, our vendors or our information systems. We may be required to incur significant costs to develop, implement and maintain AI governance, compliance, training, monitoring, cybersecurity and risk management processes, and such processes may not be effective in identifying, preventing or mitigating all AI-related risks. Any of the foregoing may have an adverse effect on our business, prospects, results of operations, and financial condition.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 51
- Share Price & Shareholder Rights - Risk 1Actions of activist stockholders have, and could continue to, impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management's attention and resources, and adversely affect our business, results of operations, financial condition, and the trading price of our common stock.
Publicly traded companies have increasingly become subject to campaigns by activist investors advocating for corporate actions such as financial restructurings, increased borrowings, special dividends, stock repurchases or even sales of assets or entire companies to third parties or the activists themselves. Responding to proxy contests and other actions by activist stockholders, including related litigation, has been and can be costly and time consuming, disrupt our operations and divert the attention of our board and senior management from the pursuit of business strategies, which could adversely affect our results of operations and financial condition. For example, in fiscal year 2024, we were engaged in a proxy contest with one of our stockholders, which was expensive and required significant time and attention by us, our board, and executive leadership team. Additionally, perceived uncertainties as to our future direction as a result of future stockholder activism or further changes to the composition of our board may lead to the perception of a change in the direction of our business, instability or lack of continuity. These uncertainties may be more acute or heightened when an activist seeks to change a majority of the board or ultimately desires to acquire the company. If individuals are elected to our board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. Additionally, actions by activist stockholders may be exploited by our competitors, cause concern to our current or potential independent consultants and customers, make it more difficult to attract and retain qualified personnel and may create adverse uncertainty for our employees. In addition, actions of activist stockholders may cause significant fluctuations in our stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business. It is possible that we could become engaged in future proxy contests with other activist stockholders, which could adversely affect our results of operations and financial condition.
- Share Price & Shareholder Rights - Risk 2Our stock price may experience future volatility.
The trading price of our common stock has historically been subject to wide fluctuations. The price of our common stock may fluctuate in the future in response to quarter-to-quarter variations in operating results, material announcements by us or competitors, governmental regulatory action, conditions in the dietary supplement industry, or other events or factors, many of which are beyond our control, and some of which do not have a strong correlation to our operating performance. We cannot predict the effect, if any, of future sales of our common stock, or the availability of our common stock for future sales, on the value of our common stock. Sales of substantial amounts of our common stock by any one or more of our stockholders, or the perception that such sales could occur, may adversely affect the market price of our common stock.
- Share Price & Shareholder Rights - Risk 3Substantial sales of shares of our common stock in the public market may impact the market price of our common stock.
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline. Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we consider appropriate. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock. Significant additional capital may be required in the future to continue our planned operations. To the extent that we raise additional capital through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted.
- Share Price & Shareholder Rights - Risk 4We cannot guarantee that our share repurchase program will be utilized to the full value approved or that it will enhance long-term stockholder value. Repurchases we consummate could increase the volatility of the price of our common stock and could have a negative impact on our available cash balance.
Our board of directors authorized a share repurchase program pursuant to which we may repurchase up to $60 million of our common stock on or before December 31, 2027. The manner, timing and amount of any share repurchases may fluctuate and will be determined by us based on a variety of factors, including the market price of our common stock, our priorities for the use of cash to support our business operations and plans, general business and market conditions, tax laws, and alternative investment opportunities. The share repurchase program authorization does not obligate us to acquire any specific number or dollar value of shares. Further, our share repurchases could have an impact on our share trading prices, increase the volatility of the price of our common stock, or reduce our available cash balance such that we will be required to seek financing to support our operations. Our share repurchase program may be modified, suspended, or terminated at any time, which may result in a decrease in the trading prices of our common stock. Even if our share repurchase program is fully implemented, it may not enhance long-term stockholder value. Additionally, repurchases are subject to the 1% Share Repurchase Excise Tax enacted by the Inflation Reduction Act, which may be offset by shares newly issued during that fiscal year (the "Share Repurchase Excise Tax"). We have and will continue to take the Share Repurchase Excise Tax into account with respect to our decisions to repurchase shares.
- Share Price & Shareholder Rights - Risk 5Additional shares that may be issued upon the exercise of currently outstanding options or upon future vesting of restricted stock units, would dilute the voting power of our currently outstanding common stock and could cause our stock price to decline.
As of June 30, 2026, we had 12.5 million shares of common stock outstanding. As of June 30, 2026, we also had stock options outstanding for an aggregate of 0.1 million shares of common stock. As of June 30, 2026, we also had time-based and performance restricted stock units outstanding that, at target-level achievement, would result in the issuance of an aggregate 0.3 million shares of common stock, which would further increase the total number of outstanding shares of our common stock. The issuance of these shares will dilute the voting power of our currently outstanding common stock and could cause our stock price to decline.
- Share Price & Shareholder Rights - Risk 6If we are unable to maintain compliance with Nasdaq requirements for continued listing, our common stock could be delisted from trading.
If our common stock was delisted from the Nasdaq Stock Market for failure to maintain compliance with its listing requirements, then there can be no assurance whether or when it would be listed again for trading on the Nasdaq or any other exchange. In addition, if our common stock were to be delisted, the market price of our shares would likely decline and become more volatile, and our stockholders may find that their ability to trade in our stock will be adversely affected. Furthermore, institutions whose charters do not allow them to hold securities in unlisted companies might sell our shares, which could have a further adverse effect on the price of our stock.
- Share Price & Shareholder Rights - Risk 7We are a "smaller reporting company" and may take advantage of certain scaled disclosures available to us. We cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
We are a "smaller reporting company" as defined in the Exchange Act. As a smaller reporting company, we are permitted to comply with scaled disclosure obligations in our SEC filings as compared to other issuers who are not smaller reporting companies, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company, the scaled disclosure in our SEC filings will result in less information about our company being available than for public companies that are not smaller reporting companies. We will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700 million as measured on the last business day of our second fiscal quarter. We cannot predict if investors will find our common stock less attractive because we will rely on certain scaled disclosures that are available to smaller reporting companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
- Share Price & Shareholder Rights - Risk 8Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.
- Share Price & Shareholder Rights - Risk 9Delaware law and provisions in our certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay, or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following: - the ability of our board to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;- the exclusive right of our board to elect a director to fill a vacancy created by the expansion of our board or the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our board;- a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;- the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board, the chairman of our board or our chief executive officer, or by stockholders holding at least 10% of the outstanding shares entitled to vote at such special meeting, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and - advance notice procedures with which stockholders must comply to nominate candidates to our board or to propose matters to be acted upon at a stockholders' meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of us. In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. These and other provisions in our certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board or initiate actions that are opposed by our then-current board, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.
- Share Price & Shareholder Rights - Risk 10If securities or industry analysts cease publishing research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock will depend in part on the research and reports published by securities or industry analysts about us or our business. Securities and industry analysts currently publish research on our company. If analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.